Retroviral Integrase
From Proteopedia
(→PFV Crystalization) |
(→PFV Crystalization) |
||
| Line 4: | Line 4: | ||
HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | ||
| - | ==PFV | + | ==PFV Crystallization== |
| - | The remarkable stability of the IN-DNA complexes were determined by observing the "in vitro" strand transfer reactions, which were classified into three modes of deproteination migration: (1) single | + | The remarkable stability of the IN-DNA complexes were determined by observing the "in vitro" strand transfer reactions, which were classified into three modes of deproteination migration: (1) single concerted events, linearized target plasmid; (2) multiple concerted events, smear; (3) half-site events: open circular DNA. Further characterization of the PFV intasome also exhibited structural substantiality which implied strong protein-protein and protein-DNA interactions despite prolonged incubation under high ionic strength conditions. |
==Impact of Structure== | ==Impact of Structure== | ||
Revision as of 00:49, 12 February 2010
Contents |
Introduction
Integrase is an essential retroviral enzyme that binds to viral DNA and inserts it into a host cell chromosome. It is produced by a class of retrovirus (like HIV) and is used by the virus to incorporate its genetic material into the host cell DNA. The host cellular machinery then produces mRNA and then protein from the incorporated genetic material, thus replicating the virus. Although several integrase inhibiting drugs have been investigated, the mechanism [responsible for strand-transfer inhibition action remain unclear] of action was not clear. On February 1st, 2010, a crystal structure of the PFV Intasome was published, paving the way for better retroviral treatments. [However, Hare et al (2010) determined the structural constituents of retroviral integration. Further elucidation of the complete structure of the retroviral integrase, and its application to regulate functional and enzymatic activities could potentially enable researchers to delay the progression of, and provide the next best medical treatment for retroviral diseases.]
HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007.
PFV Crystallization
The remarkable stability of the IN-DNA complexes were determined by observing the "in vitro" strand transfer reactions, which were classified into three modes of deproteination migration: (1) single concerted events, linearized target plasmid; (2) multiple concerted events, smear; (3) half-site events: open circular DNA. Further characterization of the PFV intasome also exhibited structural substantiality which implied strong protein-protein and protein-DNA interactions despite prolonged incubation under high ionic strength conditions.
Impact of Structure
Components
References
1.Stephen Hare, Saumya Shree Gupta1, Eugene Valkov1, Alan Engelman & Peter Cherepanov. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010/01/31/online Template:STRUCTURE 3l2q
2. http://www.isentress.com/raltegravir/isentress/consumer/index.jsp
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Rhysly Martinez, Joel L. Sussman, Alexander Berchansky, David Canner, Jordan Heard, Eugene Babcock, Garrett Asanuma
